Neuroleptic malignant syndrome during zuclopenthixol therapy in X-linked cerebral adrenoleukodystrophy

Journal of Inherited Metabolic Disease

Volumn 24, Issue 5, 2001, Pages 605-606

  Rubio Gozalbo, M E ^a   Van Waardenburg, D A ^a   Forget, P P ^a   Spaapen, L J M ^b   Verrips, A ^c   Vroomen, P C A J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Stichting Klinische Genetica   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLONAZEPAM; DANTROLENE; SIMVASTATIN; ZUCLOPENTHIXOL; CLOPENTHIXOL; NEUROLEPTIC AGENT;

ADRENOLEUKODYSTROPHY; ARTICLE; BRAIN DISEASE; CASE REPORT; DOSE RESPONSE; DRUG WITHDRAWAL; HUMAN; MALE; NEUROLEPTIC MALIGNANT SYNDROME; SCHOOL CHILD; X CHROMOSOME LINKAGE; BEHAVIOR DISORDER; CHILD; GENETICS; PSYCHOLOGICAL ASPECT;

ADRENOLEUKODYSTROPHY; ANTIPSYCHOTIC AGENTS; CASE REPORT; CHILD; CHILD BEHAVIOR DISORDERS; CLOPENTHIXOL; HUMAN; MALE; NEUROLEPTIC MALIGNANT SYNDROME; SIMVASTATIN;

EID: 0035149764     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012480130445     Document Type: Article

References (3)

1. Rhabdomyolysis and simvastatin
2. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome
3. Simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophy